India, Aug. 6 -- Pacific Biosciences of California, Inc. (PACB) announced a wider loss for the second quarter ended June 30, 2026, while the revenues were slightly down from the prior year. The company also reduced its full year revenue guidance.
PacBio's Board of Directors appointed Mark Van Oene as President and Chief Executive Officer, effective from August 5, 2026.
Company Profile
Pacific Biosciences of California, Inc. (PacBio) is a life sciences technology company that develops and commercializes sequencing systems and genomic analysis solutions. Its portfolio includes HiFi long-read sequencing, short-read sequencing, and related consumables and software for applications in human genetics, oncology, infectious disease, agriculture,...